Alkem Laboratories has announced the launch of Semaglutide injection in India for type-2 diabetes and chronic weight management. The weekly therapy is being made accessible through highly affordable pricing, with costs starting as low as INR 450 per week (INR 1,800 for a month’s dosage). The product is available under the brand names “Semasize,” “Obesema,” and “Hepaglide”, aiming to improve patient adherence and healthcare outcomes.
ALKEM Launches Semaglutide for Diabetes and Weight Management
Alkem Laboratories Limited announced on March 21, 2026, the commercial launch of Semaglutide injection in the Indian market. This drug is indicated for the treatment of type-2 diabetes mellitus and chronic weight management, administered via a once-weekly subcutaneous injection.
Affordable Pricing Strategy Revealed
The company has implemented a focused strategy to enhance accessibility by introducing highly competitive pricing. Alkem’s pre-filled disposable injection pen, containing four doses for a month, will be available at a starting price of INR 1,800. This translates to a weekly therapy cost of just INR 450. The launch is supported by the brand names “Semasize,” “Obesema,” and “Hepaglide”.
To further support cost reduction and patient adherence, Alkem is also offering a reusable injection pen option for patients requiring higher maintenance doses, allowing them to only replace the medication cartridge.
Regulatory Approvals and CEO Commentary
The launch follows the necessary approvals received from the Drug Controller General of India (DCGI) for manufacturing and marketing Semaglutide based on Phase 3 clinical trials conducted within India. The product is available only as a prescription medicine under appropriate medical supervision.
Commenting on the introduction, Dr. Vikas Gupta, Chief Executive Officer of Alkem, stated that the company aims to translate therapeutic advancements into real-world access. He emphasized that the launch of their indigenously-developed semaglutide provides a high-quality, affordable option, empowering practitioners to treat a larger section of the population.
Source: BSE
